Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWINSS extension study of subcutaneous iscalimab in Sjögren's syndrome
NL-OMON51920Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of iscalimab in Sjögren's syndrome (2 arms), sponsored by Novartis. Primary endpoints: Incidence of treatment-emergent adverse events and serious adverse events, Routine hematology and clinical chemistry laboratory results and 1 more. Started Nov 2021; status: active, not recruiting.
02
Drugs
iscalimab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON51920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51920.